SmithKline Beecham (Australia) Pty Ltd v Chipman

SmithKline Beecham (Australia) Pty Ltd, an applicant, sought judicial review of decisions made by various respondents regarding the registration of a pharmaceutical product, Arrox (paroxetine mesilate), under the Therapeutic Goods Act 1989. The case involved multiple preliminary questions concerning the applicant's standing to seek review and reconsideration of decisions made by the Therapeutic Goods Administration and the Minister for Health and Aged Care. These questions were framed within the context of statutory provisions for review and reconsideration of decisions under the Act and the Administrative Decisions (Judicial Review) Act 1977.

The court was required to determine whether the applicant had standing to seek review of three separate decisions: the initial decision to register the product, the refusal to reconsider the initial decision, and the decision to confirm the initial decision after the reconsideration period lapsed. Additionally, the court had to assess whether these decisions were subject to review under the applicable legislation and whether the applicant was aggrieved by these decisions. The court also needed to clarify whether the applicant had the requisite standing to apply for relief under section 39B of the Judiciary Act 1903 in relation to these decisions.

The court analysed the statutory framework and the specific provisions concerning review and reconsideration within the Therapeutic Goods Act. It examined the nature of the decisions made and whether they were initial decisions subject to the reconsideration process. The court also assessed the applicant's interests and whether they were affected by the decisions in question. After considering the submissions and the relevant statutory provisions, the court found that the applicant did not have standing to seek review of the decisions under the Act. Consequently, the objections to competency were disallowed, and the matter was referred for further directions concerning costs.